A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
Open Access
- 22 July 2017
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 32 (8) , 1117-1130
Abstract
Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α‐synuclein protein in biological fluids. Current knowledge and pitfalls are discussed, and selected perianalytical variables are presented systematically, including different temperature of sample collection and types of collection tubes, gradient sampling, the addition of detergent, aliquot volume, the freezing time, and the different thawing methods. We also discuss analytical confounders. We identify gaps in the knowledge and delineate specific areas that require further investigation, such as the need to identify posttranslational modifications of α‐synuclein and antibody‐independent reference methods for quantification, as well as the analysis of potential confounders, such as comorbidities, medication, and phenotypes of Parkinson's disease in larger cohorts. This review could be used as a guideline for future Parkinson's disease biomarker studies and will require regular updating as more information arises in this growing field, including new technical developments as they become available. In addition to reviewing best practices, we also identify the current technical limitations and gaps in the knowledge that should be addressed to enable accurate and quantitative assessment of α‐synuclein levels in the clinical setting. © 2017 International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- The Investigating Synuclein Consortium is initiated and funded by the Michael J. Fox Foundation for Parkinson's Research
This publication has 72 references indexed in Scilit:
- α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous systemJournal of Neural Transmission, 2012
- Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's diseaseBrain, 2011
- DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s diseaseBrain, 2010
- Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s diseaseBiochemical and Biophysical Research Communications, 2006
- Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the ratLife Sciences, 2006
- The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophyJournal of Neural Transmission, 2006
- The impact of blood contamination on the proteome of cerebrospinal fluidProteomics, 2005
- α-synuclein locus duplication as a cause of familial Parkinson's diseaseThe Lancet, 2004
- α-Synuclein Locus Triplication Causes Parkinson's DiseaseScience, 2003
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001